Hospital
Franciscan Health Munster
Franciscan Health Munster was paid $2.74M by Medicaid between Jan 2018 and Nov 2024, across 68 billing codes. Its largest line is 99283, emergency room visit (moderate) — 24% of everything it billed.
33Billing provider infoFRANCISCAN HEALTH MUNSTER
MUNSTER, IN 46321
MUNSTER, IN 46321
33aNPI1427493246assigned 05/07/2013
33bProvider typeGeneral Acute Care Hospital
28Total paid$2.74M
24GClaims49,175
24DCodes billed68
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in Indiana
Rank by total paid#48 of 69
Median peer was paid$9.76M
This provider vs. median0.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 3,859 | $82K | |
| 2019 | 3,768 | $262K | |
| 2020 | 3,399 | $191K | |
| 2021 | 3,446 | $124K | |
| 2022 | 6,782 | $260K | |
| 2023 | 15,718 | $1.01M | |
| 2024incomplete | 12,203 | $813K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 24% | 4,473 | 3,893 | $668K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 24% | 4,001 | 3,348 | $649K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 18% | 579 | 503 | $490K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 13% | 199 | 144 | $360K |
| 71045 | Radiologic examination, chest; single view | 2.4% | 412 | 357 | $66K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.1% | 798 | 627 | $59K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.8% | 748 | 645 | $48K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.7% | 9,602 | 7,057 | $46K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 1.7% | 249 | 214 | $46K |
| 80053 | Comprehensive metabolic panel | 1.6% | 6,541 | 5,079 | $44K |
| 36415 | Collection of venous blood by venipuncture | 1.2% | 10,754 | 7,827 | $33K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.0% | 356 | 305 | $29K |
56 more codes
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 238 | $23K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,544 | $19K |
| 73630 | <1% | 486 | $17K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 216 | $16K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 392 | $15K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 227 | $11K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 13 | $10K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 134 | $7K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 42 | $7K |
| 80050 | General health panel | <1% | 40 | $7K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 311 | $6K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 17 | $6K |
| 80061 | Lipid panel | <1% | 597 | $6K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 550 | $5K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 34 | $5K |
| 82607 | <1% | 350 | $3K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 14 | $3K |
| 83540 | <1% | 698 | $3K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 14 | $3K |
| 86769 | <1% | 85 | $2K | |
| 83550 | <1% | 407 | $2K | |
| 84484 | <1% | 202 | $2K | |
| 82728 | <1% | 230 | $2K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 74 | $2K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 74 | $2K |
| 81025 | <1% | 257 | $2K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 59 | $1K |
| 83690 | <1% | 324 | $1K | |
| 86003 | <1% | 13 | $1K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 12 | $1K |
| 81001 | <1% | 408 | $1K | |
| 83655 | <1% | 83 | $1K | |
| 85027 | <1% | 102 | $645.65 | |
| 85610 | <1% | 207 | $639.69 | |
| 97161 | <1% | 13 | $505.36 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 14 | $409.25 |
| 83735 | <1% | 103 | $405.58 | |
| 87510 | <1% | 31 | $404.87 | |
| 87480 | <1% | 31 | $404.87 | |
| 87660 | <1% | 31 | $404.87 | |
| 82105 | <1% | 39 | $389.01 | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 15 | $361.42 |
| 87081 | <1% | 54 | $300.98 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 27 | $284.94 |
| 86706 | <1% | 37 | $254.54 | |
| 97116 | <1% | 17 | $228.05 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 28 | $207.61 |
| 82746 | <1% | 29 | $196.52 | |
| 86780 | <1% | 14 | $185.36 | |
| 86708 | <1% | 20 | $140.26 | |
| 86850 | <1% | 14 | $32.73 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 12 | $9.66 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 99 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 131 | $0.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 144 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 106 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGOLAN, JOSEPH (CFO - NORTHWEST INDIANA)
| Provider | Location | Paid |
|---|---|---|
| Franciscan Health Dyer & Hammond | Dyer, IN | $4.52M |
| Franciscan Health Dyer & Hammond | Hammond, IN | $3.28M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.